Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss

Stock Track03-13

VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.

The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.

The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163636636?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163636636","market":"sg","top_or_hot":-1,"title":"Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss","media":"Stock Track","content":"<p>VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.</p><p>The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.</p><p>The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-13 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.</p><p>The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.</p><p>The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1163636636","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163636636","pubTimestamp":1773365728,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.The stock movement comes after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"个股追踪|维森制药-B盘中大涨5.28%尽管年度亏损仍获监管批准及商业化计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163636636","isCrawlerRequest":true}